Alexion Pharmaceuticals

Alexion became the rare disease division of AstraZeneca after being acquired by the company in 2021.1)


The company had been running clinical trials on ULTOMIRIS (ravulizumab-cwvz) in hospitalized COVID-19 patients until they were paused in January 2021 due to lack of efficacy.2)

Payments from Alexion

The following is a developing list of individuals and organizations that Alexion has given money to related to the COVID-19 pandemic:

Name Type Amount Description
Ronald McDonald House Charities Grant $200,000.00 Alexion awarded RMHC a Rare Belonging® grant in 2020.3)
Kemp, A. (2021, July 21). Acquisition of Alexion completed. AstraZeneca.
Goulart, M. (2021, January 13). Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19. Alexion Pharmaceuticals, Inc.
Corporate Sponsors of RMHC. Ronald McDonald House Charities. Retrieved January 17, 2022, from
Back to top